CNBX Pharmaceuticals Inc.
CNBX
$0.0005
$0.000125.00%
OTC PK
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -- |
| SG&A Expenses | -63.07% | -51.57% | -75.29% | -24.84% | -50.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.47% | -73.82% | -85.92% | -79.92% | -68.48% |
| Operating Income | 73.47% | 68.65% | 78.59% | 67.49% | 12.02% |
| Income Before Tax | 54.29% | 78.56% | 80.73% | 89.44% | 15.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.29% | 78.56% | 80.73% | 89.44% | 15.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.29% | 78.56% | 80.73% | 89.44% | 15.58% |
| EBIT | 73.47% | 68.65% | 78.59% | 67.49% | 12.02% |
| EBITDA | 85.36% | 73.10% | 85.80% | 57.32% | -14.43% |
| EPS Basic | 66.67% | 79.05% | 82.81% | 92.31% | 74.85% |
| Normalized Basic EPS | 65.38% | 65.85% | 82.50% | 81.54% | 75.00% |
| EPS Diluted | 66.67% | 79.05% | 82.81% | 92.31% | 74.85% |
| Normalized Diluted EPS | 65.38% | 65.85% | 82.50% | 81.54% | 75.00% |
| Average Basic Shares Outstanding | 36.92% | 3.58% | 12.07% | 33.99% | 235.76% |
| Average Diluted Shares Outstanding | 36.92% | 3.58% | 12.07% | 33.99% | 235.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |